Under the agreement, Interpace Diagnostics’ thyroid and pancreas tests will be covered by BCBS’ 36 independent companies across the U.S.
“We are excited about our evolving relationship with Blue Cross and Blue Shield’s Evidence Street which, we believe, will help ensure that we continue to develop and provide the information and data necessary to support and secure broader based insurance coverage and reimbursement for all of our products,” said Jack Stover, president and CEO of Interpace Diagnostics.
More articles on payer issues:
BCBS, Texas Health Resources settle contract dispute
CBO blog offers guidance on ACA replacement proposals for refundable tax credits
How the ‘big 5’ payers performed financially in 2016
